Cellvizio regulatory update

Mauna Kea said China's State Food and Drug Administration (SFDA) approved Cellvizio optical biopsy device for gastrointestinal and pulmonary use. The biotech also said it partnered with the Fujifilm (China) Investment Co. Ltd. subsidiary of Fujifilm Holdings Corp. (Tokyo:4901, Tokyo, Japan) to commercialize the product in China, where it is now available. Mauna Kea will manufacture Cellvizio, while Fuji will distribute the device. Mauna Kea declined to disclose financial details. ...